Details for New Drug Application (NDA): 020413
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
The generic ingredient in ZERIT is stavudine. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the stavudine profile page.
Summary for 020413
Tradename: | ZERIT |
Applicant: | Bristol |
Ingredient: | stavudine |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 020413
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SOLUTION;ORAL | Strength | 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Sep 6, 1996 | TE: | RLD: | Yes |
Expired US Patents for NDA 020413
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol | ZERIT | stavudine | FOR SOLUTION;ORAL | 020413-001 | Sep 6, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription